Q-omics provides the consensus-scored SFR1P1 profile across patient tissues and cancer cell-line models. SFR1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SFR1P1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, SFR1P1 RNA expression shows 9,878 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight STAD, KIRC, and LAML as cancer lineages where SFR1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFR1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFR1P1 survival associations across molecular data types. SFR1P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFR1P1 RNA expression–survival associations across cancer types. High SFR1P1 expression shows unfavorable associations in UCS, UCEC, THCA and ACC, but favorable associations in STAD and COAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for SFR1P1 RNA expression.
This table summarizes SFR1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SFR1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFR1P1 shows lower tumor expression in COAD, THCA, ESCA and LUAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher SFR1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .001).
This table shows molecular features associated with SFR1P1 in patient tissues and cancer cell lines. In patient samples, SFR1P1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
